1. Home
  2. FINW vs SLN Comparison

FINW vs SLN Comparison

Compare FINW & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FINW

FinWise Bancorp

HOLD

Current Price

$14.50

Market Cap

235.7M

Sector

Finance

ML Signal

HOLD

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$6.81

Market Cap

236.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FINW
SLN
Founded
1999
1994
Country
United States
United Kingdom
Employees
N/A
116
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
235.7M
236.2M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
FINW
SLN
Price
$14.50
$6.81
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$42.60
AVG Volume (30 Days)
20.8K
184.1K
Earning Date
04-30-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
21.51
N/A
EPS
0.20
N/A
Revenue
N/A
N/A
Revenue This Year
$160.48
N/A
Revenue Next Year
$35.27
N/A
P/E Ratio
$72.20
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.82
$4.19
52 Week High
$22.49
$8.40

Technical Indicators

Market Signals
Indicator
FINW
SLN
Relative Strength Index (RSI) 53.22 52.19
Support Level $12.82 $5.76
Resistance Level $17.39 $7.53
Average True Range (ATR) 0.49 0.58
MACD 0.20 0.01
Stochastic Oscillator 93.01 66.18

Price Performance

Historical Comparison
FINW
SLN

About FINW FinWise Bancorp

FinWise Bancorp is an independent bank that provides a full range of banking services to individual and commercial customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Share on Social Networks: